SpringWorks Therapeutics has filed a patent for chlorinated tetralin compounds and pharmaceutical compositions. The patent claims have been canceled. GlobalData’s report on SpringWorks Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on SpringWorks Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. SpringWorks Therapeutics's grant share as of September 2023 was 6%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230310379A1) describes a method for treating desmoid tumors in patients. The method involves administering a pharmaceutical composition containing a compound of Formula IB or a pharmaceutically acceptable salt thereof.
The patent claims specify different amounts of the compound of Formula IB or its salt in the pharmaceutical composition. Claims 18 to 22 state that the compound should be present in an amount ranging from about 1 µg to about 300 µg. Claims 23 to 27 mention that the pharmaceutical composition may also include nirogacestat or a pharmaceutically acceptable salt thereof. In this case, the compound of Formula IB or its salt should be present in an amount ranging from about 1 µg to about 250 µg. Claims 28 to 32 state that the compound should be present in an amount ranging from about 1 µg to about 150 µg. Finally, claims 33 to 37 specify that the compound should be present in an amount ranging from about 1 µg to about 50 µg. In all these claims, the pharmaceutical composition is said to contain 50 mg of nirogacestat or a pharmaceutically acceptable salt thereof.
Desmoid tumors are rare, locally aggressive tumors that can occur in various parts of the body. They are characterized by the excessive growth of fibrous tissue. Currently, treatment options for desmoid tumors are limited, and there is a need for more effective therapies. The filed patent proposes a method that involves the administration of a pharmaceutical composition containing a compound of Formula IB or its salt. The patent claims specify different dosage ranges for the compound, depending on whether it is administered alone or in combination with nirogacestat. The compound of Formula IB is believed to have therapeutic potential in the treatment of desmoid tumors. However, further research and clinical trials would be necessary to evaluate the safety and efficacy of this method. If granted, this patent could potentially provide a new treatment option for patients with desmoid tumors.
To know more about GlobalData’s detailed insights on SpringWorks Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
